PLCG2 and marginal zone lymphoma: Mutations in BTK at the binding site (BTKC481S mutation) or mutations in PLCG2, the kinase immediately downstream of BTK, are often seen in patients with CLL, MCL, WM, or marginal zone lymphoma (MZL) who developed resistance to ibrutinib[37,38].